Which has preferable earnings & valuation, ONC or QGEN?

Qiagen has lower revenue, but higher earnings than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.74B 5.35 $286.93M $4.47 62.62 Qiagen $2.09B 3.88 $424.88M $1.91 20.61

Is ONC or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Qiagen 19.16% 14.40% 8.40%

Does the media favor ONC or QGEN?

In the previous week, BeOne Medicines had 10 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for BeOne Medicines and 4 mentions for Qiagen. BeOne Medicines' average media sentiment score of 0.13 beat Qiagen's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, QGEN or MRNA?

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 Moderna $1.94B 13.73 -$2.82B -$8.15 N/A

Is QGEN or MRNA more profitable?

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Moderna -143.55% -26.64% -19.32%

Does the media refer more to QGEN or MRNA?

In the previous week, Moderna had 19 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Qiagen. Moderna's average media sentiment score of 0.50 beat Qiagen's score of 0.00 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 9 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, QGEN or BNTX?

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 BioNTech $2.81B 8.22 -$1.29B -$5.88 N/A

Is QGEN or BNTX more profitable?

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% BioNTech -44.39% -5.30% -4.62%

Does the media refer more to QGEN or BNTX?

In the previous week, Qiagen had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Qiagen's score of 0.00 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, QGEN or ROIV?

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 Roivant Sciences $8.26M 2,966.77 -$299.77M -$0.60 N/A

Is QGEN or ROIV more profitable?

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media refer more to QGEN or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.12 beat Qiagen's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, QGEN or INSM?

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.88 $424.88M $1.91 20.61 Insmed $606.42M 36.95 -$1.28B -$5.75 N/A

Is QGEN or INSM more profitable?

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Insmed -144.44% -130.11% -51.57%

Does the media favor QGEN or INSM?

In the previous week, Insmed had 13 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 4 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.00 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Qiagen (QGEN) Competitors

$39.36 +0.42 (+1.07%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$39.00 -0.36 (-0.91%)

As of 06/26/2026 07:57 PM Eastern

Compare

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

Should you buy Qiagen stock or one of its competitors? MarketBeat compares Qiagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qiagen include BeOne Medicines (ONC), Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Qiagen compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, BeOne Medicines had 10 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for BeOne Medicines and 4 mentions for Qiagen. BeOne Medicines' average media sentiment score of 0.13 beat Qiagen's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has a net margin of 19.16% compared to BeOne Medicines' net margin of 8.94%. Qiagen's return on equity of 14.40% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Qiagen	19.16%	14.40%	8.40%

BeOne Medicines currently has a consensus target price of $390.00, suggesting a potential upside of 39.34%. Qiagen has a consensus target price of $43.15, suggesting a potential upside of 9.62%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Qiagen has lower revenue, but higher earnings than BeOne Medicines. Qiagen is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74B	5.35	$286.93M	$4.47	62.62
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61

Summary

BeOne Medicines beats Qiagen on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Moderna?

Qiagen (NYSE:QGEN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A

70.0% of Qiagen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 19 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Moderna and 4 mentions for Qiagen. Moderna's average media sentiment score of 0.50 beat Qiagen's score of 0.00 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen presently has a consensus price target of $43.15, indicating a potential upside of 9.62%. Moderna has a consensus price target of $37.13, indicating a potential downside of 44.80%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Qiagen beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to BioNTech?

Qiagen (NYSE:QGEN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Qiagen pays an annual dividend of $0.26 per share and has a dividend yield of 0.7%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. Qiagen pays out 13.6% of its earnings in the form of a dividend. BioNTech pays out -26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. BioNTech is clearly the better dividend stock, given its higher yield and lower payout ratio.

Qiagen currently has a consensus target price of $43.15, suggesting a potential upside of 9.62%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
BioNTech	$2.81B	8.22	-$1.29B	-$5.88	N/A

In the previous week, Qiagen had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Qiagen and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Qiagen's score of 0.00 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
BioNTech	-44.39%	-5.30%	-4.62%

Qiagen has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Summary

BioNTech beats Qiagen on 10 of the 18 factors compared between the two stocks.

How does Qiagen compare to Roivant Sciences?

Qiagen (NYSE:QGEN) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 4 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.12 beat Qiagen's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Qiagen presently has a consensus price target of $43.15, suggesting a potential upside of 9.62%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential downside of 1.41%. Given Qiagen's higher possible upside, equities analysts plainly believe Qiagen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Qiagen has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Qiagen beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Insmed?

Qiagen (NYSE:QGEN) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Insmed had 13 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for Insmed and 4 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.00 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen presently has a consensus target price of $43.15, suggesting a potential upside of 9.62%. Insmed has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.88	$424.88M	$1.91	20.61
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Insmed	-144.44%	-130.11%	-51.57%

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Qiagen beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$8.02B	$3.55B	$6.70B	$23.23B
Dividend Yield	0.68%	2.25%	2.67%	4.10%
P/E Ratio	20.56	21.56	25.76	31.64
Price / Sales	3.88	334.67	559.68	109.21
Price / Cash	11.44	137.38	46.99	24.58
Price / Book	2.20	8.34	10.77	4.74
Net Income	$424.88M	$23.91M	$3.57B	$1.07B
7 Day Performance	6.37%	3.38%	2.15%	0.99%
1 Month Performance	8.87%	1.51%	1.06%	0.86%
1 Year Performance	-21.72%	65.14%	34.16%	25.19%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	3.2314 of 5 stars	$39.36 +1.1%	$43.15 +9.6%	-22.2%	$8.02B	$2.09B	20.56	5,654	Analyst Upgrade
ONC BeOne Medicines	4.7782 of 5 stars	$271.80 +0.6%	$390.00 +43.5%	+10.0%	$29.64B	$5.34B	60.81	12,000	Insider Trade
MRNA Moderna	0.9825 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+144.3%	$25.38B	$1.94B	N/A	4,700	Trending News Analyst Forecast
BNTX BioNTech	4.2741 of 5 stars	$90.19 -0.8%	$129.56 +43.7%	-14.1%	$22.98B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0444 of 5 stars	$31.25 -0.6%	$33.59 +7.5%	+193.7%	$22.61B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Qiagen compare to BeOne Medicines?

Summary

How does Qiagen compare to Moderna?

Summary

How does Qiagen compare to BioNTech?

Summary

How does Qiagen compare to Roivant Sciences?

Summary

How does Qiagen compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qiagen (QGEN) Competitors

QGEN vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Qiagen compare to BeOne Medicines?

Does the media favor ONC or QGEN?

Is ONC or QGEN more profitable?

Do analysts recommend ONC or QGEN?

Which has more risk & volatility, ONC or QGEN?

Do institutionals and insiders hold more shares of ONC or QGEN?

Which has preferable earnings & valuation, ONC or QGEN?

Summary

How does Qiagen compare to Moderna?

Which has more volatility and risk, QGEN or MRNA?

Which has stronger valuation & earnings, QGEN or MRNA?

Do insiders & institutionals hold more shares of QGEN or MRNA?

Does the media refer more to QGEN or MRNA?

Do analysts prefer QGEN or MRNA?

Is QGEN or MRNA more profitable?

Summary

How does Qiagen compare to BioNTech?

Do insiders & institutionals have more ownership in QGEN or BNTX?

Is QGEN or BNTX a better dividend stock?

Do analysts recommend QGEN or BNTX?

Which has higher valuation and earnings, QGEN or BNTX?

Does the media refer more to QGEN or BNTX?

Is QGEN or BNTX more profitable?

Which has more risk and volatility, QGEN or BNTX?

Summary

How does Qiagen compare to Roivant Sciences?

Do insiders & institutionals hold more shares of QGEN or ROIV?

Which has higher valuation & earnings, QGEN or ROIV?

Does the media refer more to QGEN or ROIV?

Is QGEN or ROIV more profitable?

Do analysts recommend QGEN or ROIV?

Which has more risk & volatility, QGEN or ROIV?

Summary

How does Qiagen compare to Insmed?

Does the media favor QGEN or INSM?

Do analysts rate QGEN or INSM?

Which has higher earnings & valuation, QGEN or INSM?

Is QGEN or INSM more profitable?

Which has more risk & volatility, QGEN or INSM?

Do insiders and institutionals hold more shares of QGEN or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools